A Game-Changer for Diabetes: Polymer Delivers Insulin Painlessly Through Skin
November 25, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Renormax
Synonyms :
spirapril
Class :
Angiotensin-Converting Enzyme Inhibitors, Antihypertensive Agents
Brand Name :
Renormax
Synonyms :
spirapril
Class :
Angiotensin-Converting Enzyme Inhibitors, Antihypertensive Agents
Dosage Forms & StrengthsÂ
Tablet Â
2 mg Â
4 mg Â
6 mg Â
Take a dose of 3 to 6 mg once in a day
Not determined Â
Refer to adult dosingÂ
may increase the adverse effect of angiotensin ii receptor blockers
may increase the adverse effect of angiotensin ii receptor blockers
may increase the adverse effect of angiotensin ii receptor blockers
may increase the adverse effect of angiotensin ii receptor blockers
may increase the adverse effect of angiotensin ii receptor blockers
may increase the adverse effect of angiotensin ii receptor blockers
may increase the adverse effect of angiotensin ii receptor blockers
spirapril: it may increase the risk of methemoglobinemia associated agents
spirapril: it may increase the risk of methemoglobinemia associated agents
spirapril: it may increase the risk of methemoglobinemia associated agents
spirapril: it may increase the risk of methemoglobinemia associated agents
spirapril: it may increase the risk of methemoglobinemia associated agents
may increase the toxic effect of angiotensin receptor II blockers
may enhance the hypotensive effect when combined with sparsentan
may have an increased hyperkalemic effect when combined with angiotensin-converting enzyme inhibitors
may have an increasingly adverse effect when combined with angiotensin-converting enzyme inhibitors
may have an increasingly adverse effect when combined with angiotensin-converting enzyme inhibitors
may have an increasingly adverse effect when combined with angiotensin-converting enzyme inhibitors
may have an increasingly adverse effect when combined with angiotensin-converting enzyme inhibitors
may have an increasingly adverse effect when combined with angiotensin-converting enzyme inhibitors
may diminish the serum concentration when combined with angiotensin-converting enzyme inhibitors
may have an increasingly adverse effect when combined with ACE inhibitors
may enhance the concentration of serum when combined with lithium
grass pollens allergen extractÂ
may have an increasingly adverse effect when combined with grass pollen extract
choline magnesium trisalicylate
may enhance the nephrotoxic effect of ACE inhibitors
may enhance the adverse/toxic effect of NSAIDs
may enhance the adverse/toxic effect of NSAIDs
may enhance the adverse/toxic effect of NSAIDs
may enhance the adverse/toxic effect of NSAIDs
may enhance the adverse/toxic effect of NSAIDs
may enhance the bradycardic effect of beta-blockers
may enhance the bradycardic effect of beta-blockers
may enhance the bradycardic effect of beta-blockers
may enhance the bradycardic effect of beta-blockers
may enhance the bradycardic effect of beta-blockers
may increase the risk of adverse/toxic effects
may increase the risk of adverse/toxic effects
may increase the risk of adverse/toxic effects
may increase the risk of adverse/toxic effects
may increase the risk of adverse/toxic effects
may have an increased therapeutic effect when combined with angiotensin II receptor blocker
may have an increased therapeutic effect when combined with angiotensin II receptor blocker
may have an increased therapeutic effect when combined with angiotensin II receptor blocker
may have an increased therapeutic effect when combined with angiotensin II receptor blocker
may have an increased therapeutic effect when combined with angiotensin II receptor blocker
may have an increased hyperkalemic effect when combined with angiotensin-converting enzyme inhibitors
may have an increased hyperkalemic effect when combined with angiotensin-converting enzyme inhibitors
may have an increased hyperkalemic effect when combined with angiotensin-converting enzyme inhibitors
may have an increasingly adverse effect when combined with NSAIDs
may have an increased nephrotoxic effect when combined with sodium phosphates
may have an increased nephrotoxic effect when combined with sodium phosphates
may have an increased nephrotoxic effect when combined with sodium phosphates
may have an increased nephrotoxic effect when combined with sodium phosphates
may have an increased nephrotoxic effect when combined with sodium phosphates
may increase the hypotensive effect of angiotensin-converting enzyme inhibitors
may increase the hypotensive effect of angiotensin-converting enzyme inhibitors
may increase the hypotensive effect of angiotensin-converting enzyme inhibitors
may have an increasingly adverse effect when combined with NSAIDs
may increase the nephrotoxic effect of salicylates
may have an increased therapeutic effect when combined with angiotensin II receptor blocker
may have an increased therapeutic effect when combined with angiotensin II receptor blocker
may decrease the antihypertensive effect when combined with angiotensin-converting enzyme inhibitors
may have an increased myelosuppressive effect when combined with azathioprine
may have an increased hyperkalemic effect when combined with angiotensin-converting enzyme inhibitors
spironolactone and hydrochlorothiazide
may increase the hyperkalemic effect of ACE Inhibitors
may increase the hyperkalemic effect of ACE Inhibitors
may increase the hyperkalemic effect of ACE Inhibitors
may increase the hyperkalemic effect of ACE Inhibitors
may increase the hyperkalemic effect of ACE Inhibitors
may increase the hyperkalemic effect when combined with ace inhibitors
may have an increased hyperkalemic effect when combined with angiotensin-converting enzyme inhibitors
drospirenone/ethinyl estradiol/levomefolateÂ
may increase the hyperkalemic effect of Drospirenone-Containing Products
empagliflozin and linagliptinÂ
may increase the toxic effects of dipeptidyl peptidase-IV inhibitors
choline magnesium trisalicylate
may have an increased nephrotoxic effect when combined with angiotensin-converting enzyme inhibitors
may have an increasingly adverse effect when combined with angiotensin-converting enzyme inhibitors
may have an increasingly adverse effect when combined with angiotensin-converting enzyme inhibitors
may have an increased hypotensive effect when combined with ACE inhibitors
may have an increased hypotensive effect when combined with ACE inhibitors
may have an increased hypotensive effect when combined with ACE inhibitors
may have an increased hypotensive effect when combined with angiotensin-converting enzyme inhibitors
may have an increased hypotensive effect when combined with angiotensin-converting enzyme inhibitors
sodium ferric gluconate complexÂ
concomitant administration of ACE inhibitors with sodium ferric gluconate complex should be used with caution as it may cause possible adverse reactions like hypersensitivity and low blood pressure
may have an increased hyperkalemic effect when combined with angiotensin-converting enzyme inhibitors
may have an increased hyperkalemic effect when combined with angiotensin-converting enzyme inhibitors
may have an increased hyperkalemic effect when combined with angiotensin-converting enzyme inhibitors
ergotamine: it may decrease the antihypertensive activities of spirapril
esmolol: it may increase the hypotensive activities of spirapril
fluspirilene: it may increase the hypotensive activities of spirapril
formoterol: it may increase the hypotensive activities of spirapril
fostamatinib: it may increase the hypotensive activities of spirapril
furosemide: it may increase the hypotensive activities of spirapril
Actions and SpectrumÂ
spirapril inhibits the action of ACE, an enzyme responsible for converting angiotensin I to angiotensin II. Â
Angiotensin II is a potent vasoconstrictor, and by reducing its levels, spirapril causes blood vessels to dilate, reducing blood pressure.
Frequency not defined Â
None
Black Box WarningÂ
None
Contraindication/Caution:Â
Contraindication:Â
Caution:Â
Pregnancy consideration:Â
Pregnancy category: N/AÂ
Lactation: Excretion into human milk is unknown Â
Pregnancy Categories:        Â
Category A: well-controlled and Satisfactory studies show no risk to the fetus in the first or later trimester.Â
Category B: there was no evidence of risk to the fetus in animal studies, and there were not enough studies on pregnant women. Â
Category C: there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.Â
Category D: adequate data with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.Â
Category X: Drugs listed in this category outweigh the risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.Â
Category N: There is no data available for the drug under this category.Â
Pharmacology Â
spirapril causes blood vessels to relax and dilate due to a reduction in angiotensin II levels. This vasodilation decreases peripheral resistance, which lowers blood pressure. It also reduces the secretion of aldosterone, a hormone that leads to sodium and water retention. Â
PharmacodynamicsÂ
spirapril is an angiotensin-converting enzyme (ACE) inhibitor.Â
Angiotensin II stimulates the release of aldosterone, a hormone that leads to sodium and water retention, contributing to increased blood pressure. Â
PharmacokineticsÂ
Absorption  Â
spirapril is absorbed into the bloodstream after oral administration.Â
DistributionÂ
spirapril is distributed throughout the body.Â
MetabolismÂ
spirapril is metabolized in the liver.Â
Elimination and excretionÂ
spirapril eliminated through the kidneys.
AdministrationÂ
spirapril is available in tablet form for oral intake.Â
Patient information leafletÂ
Generic Name: spiraprilÂ
Why do we use spirapril?Â
spirapril is indicated to lower high blood pressure. It relaxes blood vessels and reducing peripheral resistance, which helps to lower blood pressure. spirapril can also be used in the management of congestive heart failure.Â
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
